C2i Genomics Named to the 2021 CB Insights Digital Health 150 List of Most Innovative Digital Health Startups

CB Insights today named C2i Genomics, a cancer intelligence company, to its third annual Digital Health 150, which showcases the 150 most promising private digital health companies in the world. This year’s Digital Health 150 was unveiled live during CB Insights’ annual Future of Health event. 

The 2021 Digital Health 150 cohort has raised roughly $14.9 billion in aggregate funding across 522 deals since 2016, and includes startups at various investment stages of development, from early-stage to well-funded unicorns. Companies this year include startups working on data integration & analytics, hybrid virtual/in-person care, digital therapeutics, clinical intelligence, and more.

“The C2-Intelligence Platform leverages a unique model of data analytics that gives cancer centers and diagnostic partners all over the world the ability to monitor cancer treatment and provide more effective personalized treatments,” said Asaf Zviran, founder and CEO of C2i Genomics. “This has been a huge year of growth for C2i, from scaling the platform through funding and partnerships to expanding our commercial reach and research to find more impactful and accurate cancer monitoring. In 2022 you can expect us to broaden our product portfolio and expand the accessibility for our test to more patients worldwide…”

C2i Genomics has built a breakthrough new diagnostic system that applies AI pattern recognition and whole-genome analysis to just a 2 ml blood sample to provide up to 100x more sensitive cancer detection than competing technologies. C2i’s technology also eliminates the need to develop a patient-specific assay, enabling high performance and personalized monitoring with reduced operational complexity and rapid turnaround. In the past year, the company has raised $100 million to accelerate the clinical development and commercialization of its cancer intelligence platform, as well as partnered with leading clinical labs and diagnostic companies such as NovogeneAIT Genomics, Premier, Inc. and NuProbe Global.

“This year’s Digital Health 150 is one of our most expansive yet, spotlighting 16 categories including virtual care, clinical trials tech, and workflow automation, as well as adding new categories such as home health tech and computer-aided imaging,” said Brian Lee, SVP of CB Insights’ Intelligence Unit. “Last year’s class has seen more than 20 exits, raised an additional $18.6 billion in aggregate funding, and announced over 250 partnerships since being recognized, and we’re excited to see the future success of this year’s winners.”

Through an evidence-based approach, the CB Insights research team selected the Digital Health 150 from a pool of over 11,000 companies, including applicants and nominees. They were chosen based on several factors, including data submitted by the companies, company business models and momentum in the market, and Mosaic scores, CB Insights’ proprietary algorithm that measures the overall health and growth potential of private companies.

2021 Digital Health 150 Investment Highlights:

• Unicorns: 17 of the 150 companies (11%) are valued at or above $1 billion as of their latest funding rounds.
• Funding trends: In 2021 year-to-date (YTD), these 150 private companies have raised $9.2 billion in equity funding across 153 deals (as of 11/19/21).
• Mega-rounds: Since 2020, there have been 39 mega-round ($100 million+) equity investments to this year’s Digital Health 150, with 31 (79%) of them taking place in 2021 YTD.
• Global representation: 23% of the 2021 Digital Health 150 are based outside the US. After the US, the UK is home to the most Digital Health 150 companies (9), followed by India (4). This year’s winners are based in 18 countries, including China, Israel, Nigeria, Germany, Argentina, and New Zealand.
• Top VC investor: General Catalyst is the most active investor in this year’s Digital Health 150 companies, having invested in 39 deals since 2016. 

About CB Insights
CB Insights builds software that enables the world’s best companies to discover, understand, and make technology decisions with confidence. By marrying data, expert insights, and work management tools, clients manage their end-to-end technology decision-making process on CB Insights. To learn more, please visit www.cbinsights.com.

CB Insights Press Contact:
press@cbinsights.com
 
About C2i Genomics 
Founded in 2019, C2i Genomics has created the world’s leading cancer treatment intelligence platform that uses low-input blood (only 2mL blood) whole-genome sequencing to provide up to 100x more sensitive detection than competing liquid biopsy companies. With a headquarters in NYC, CLIA lab in Cambridge MA, and an R&D center in Israel, C2i’s SaaS solution utilizes a cloud-based platform to perform cancer tumor burden monitoring on a global scale, leveraging the thousands of already installed genome sequencers around the world. Using cutting-edge scientific breakthroughs, growing genomic and clinical databases, and sophisticated computation and AI, C2i enables high precision personalized medicine, reduced cancer treatment costs, and accelerated drug development. For more information, please visit www.c2i-genomics.com. 
 

Contact Information

Jessica Flick

PR for C2i Genomics

VSC for C2i Genomics

Contact via E-mail